<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In order to evaluated the curative effect of rhIL-11 (Mega) on <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo> in <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> (CAA) patients, ten CAA cases with <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo> after administration of conventional drugs were selected and subcutaneously injected 0.75 mg Mega per day in 1 - 2 courses of treatment on the basis of conventional therapy </plain></SENT>
<SENT sid="1" pm="."><plain>Results showed that platelet counts were obviously increased and the <z:mp ids='MP_0001914'>bleeding</z:mp> symptoms were alleviated in <z:hpo ids='HP_0000001'>all</z:hpo> CAA patients after application of Mega for treatment </plain></SENT>
<SENT sid="2" pm="."><plain>In conclusion, the rhIL-11 (Mega) could be used as an effective drug for treatment of <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo> in CAA patients </plain></SENT>
</text></document>